Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPH5301 + chemotherapy + trastuzumab
- Development stage
- Unknown
- Lead developer
- Innate Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
IPH5301 is a monoclonal antibody that targets and blocks CD73, an extracellular enzyme expressed in the tumor microenvironment on both tumor-infiltrating immune cells and stromal cells. CD73 contributes to immunosuppression by degrading adenosine monophosphate (AMP) to adenosine, which inhibits anti-tumor immune responses. By inhibiting CD73, IPH5301 aims to promote anti-tumor immunity across a range of solid tumors. The drug is being developed by Innate Pharma and is currently in Phase 1 clinical trials for use alone or in combination with chemotherapy and trastuzumab in patients with advanced or metastatic HER2-positive cancers[1][2][4][6].
- Other names
- IPH-5301IPH5301IPH 5301
02
Targets
NT5E (Cluster of Differentiation 73)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on IPH5301 + chemotherapy + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPH5301 + chemotherapy + trastuzumab.